linjc16/ctgov huggingface dataset:
Composition of Functional Tooth Units and Nutrient Intake in Older Men

Study Overview
=================
Brief Summary
-----------------
Various definitions of poor dentition in older adults has been linked with inadequate intake of nutrients and poor diet quality. This study aims to look at the associations between poor dentition as defined by the composition of functional tooth units, and dietary intake of nutrients in community dwelling older men.

Detailed Description
-----------------
Poor dentition, defined by numbers of teeth, functional tooth units or edentulism has been previously shown to be associated with poor intakes of nutrients in older adults, including but not limited to vitamin C, calcium, fibre, protein, zinc and folate. Similar findings have been found when poor dentition is defined by the presence of a prosthesis. Reasons for this inverse relationship include poor denture quality, reduced chewing capacity, or the inadequacy of prosthesis to replace natural teeth. However limited studies have looked at how the composition (natural verses prosthetic) of functional tooth units is associated with nutrient intake. A cross sectional analysis of a cohort of male older adults, participating in an ongoing longitudinal study, was conducted to investigate nutrition and oral health associations, including the relationship between the composition of functional tooth units and nutrient intake.

Official Title
-----------------
Associations Between the Composition of Functional Tooth Units and Nutrient Intake in Older Men: the Concord Health and Ageing in Men Project.

Conditions
-----------------
Oral Health of Older Men, Dietary Assessment of Older Men

Intervention / Treatment
-----------------
* Other: Composition of functional tooth units


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Exclusion Criteria: Moved inter or intrastate (moved out of study area) Death Refused to participate previously withdrawn

Ages Eligible for Study
-----------------
Minimum Age: 78 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Composition of functional tooth units|Composition of functional tooth units measured by trained oral health therapists and was categorised into 3 groups: Group A: Natural units only Group B: Natural & Prosthetic units present Group C: No natural units present|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dietary intake of nutrients | A diet history was performed, and data entered into a database which provided daily average nutrient intakes. | 45 minute interview on 1 day (cross-sectional). | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diet, Oral Health, Nutrition, Dentition
Study to Establish Whether the Use of T-Tube in Bile Duct Anastomosis in Liver Transplantation Decreases Morbidity

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to compare the incidence and severity of biliary complications due to liver transplantation after choledochocholedochostomy with or without a T-tube. A per-protocol analysis was designed for recipients of orthotopic liver transplantation in a single center, who were randomly assigned to choledochocholedochostomy with or without a T-tube. It is a prospective and randomized study.

Official Title
-----------------
Prospective and Randomized Trial on the Usefulness of T-Tube in the Bile Duct Anastomosis in Liver Transplantation Procedure.

Conditions
-----------------
Evidence of Liver Transplantation

Intervention / Treatment
-----------------
* Device: Choledocho-choledochostomy with T-tube
* Device: Choledocho-choledochostomy without T-tube


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Recipients of a deceased full-size liver graft Aged > 18 years Exclusion Criteria: Age < 18 years Retransplantation Primary sclerosing cholangitis Fulminant hepatic failure Technical need for a hepaticojejunostomy Splitted graft Reduced-size graft More than one organ transplantation Living donation Finding of a large difference (twice the size) in common bile duct diameters between the graft and the recipient

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 67 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Bile duct anastomosis with T-tube<br> | Device: Choledocho-choledochostomy with T-tube<br>* In the anastomosis between the common bile duct of the graft and the common bile duct of the recipient, a tutorial T-tube is inserted in the bile duct lumen and will be removed from the patient on third month postoperatively.<br>|
| Active Comparator: Bile duct anastomosis without T-tube<br> | Device: Choledocho-choledochostomy without T-tube<br>* The termino-terminal anastomosis between common bile duct of the graft and common bile duct of the recipient is performed without any T-tube.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all morbidity related to bile duct | All the complications related to bile duct that appear after transplantation will be recorded in both groups. All patients will be followed up for the first 12 months after transplantation. | The first year after liver transplantation procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bile duct anastomosis, Biliary complications
A Pilot Study to Explore the Role of Gut Flora in Parkinson's Disease

Study Overview
=================
Brief Summary
-----------------
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Parkinson's Disease.

Detailed Description
-----------------
The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to the information provided in surveys and in medical records regarding Parkinson's Disease.

Official Title
-----------------
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Parkinson's Disease

Conditions
-----------------
Parkinson Disease, Parkinsons Disease With Dementia, Parkinson-Dementia Syndrome, Parkinson Disease 2, Parkinson Disease 3, Parkinson Disease 4

Intervention / Treatment
-----------------
* Other: No Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study Male or female patients of any age (interest is given to children to compare with mothers). Diagnosis of Parkinson's Disease Exclusion Criteria: Refusal to sign informed consent form History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy. Postoperative stoma, ostomy, or ileoanal pouch Participation in any experimental drug protocol within the past 12 weeks Treatment with total parenteral nutrition Any clinically significant evidence of disease that could interfere with the subject's ability to enter the trial Inability to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br>Patients who have been diagnosed with Parkinson's Disease | Other: No Intervention<br>* There is no intervention for this study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of Microbiome to Parkinson's Disease via Relative Abundance Found in Microbiome Sequencing | Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the gut microbiome. These data will then be categorized among specific disease types | One Year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Validation of Sequencing Methods | To validate the methods used to sequence samples | One year |
Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Evaluate the effects of cladribine (2-chlorodeoxyadenosine; 2-CdA) on biochemical, radiologic, and histologic parameters in patients with early stage primary sclerosing cholangitis.

Detailed Description
-----------------
PROTOCOL OUTLINE: Patients are treated with subcutaneous injections of cladribine (2-chlorodeoxyadenosine; 2-CdA) for 5 consecutive days every month for 3 months.

Conditions
-----------------
Cholangitis, Sclerosing

Intervention / Treatment
-----------------
* Drug: cladribine


Participation Criteria
=================
Eligibility Criteria
-----------------
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Stage I-III primary sclerosing cholangitis Radiologically and pathologically documented No concomitant liver disease, e.g.: Viral hepatitis Autoimmune hepatitis Primary biliary cirrhosis Cirrhosis Portal hypertension or associated complications Jaundice caused by dominant stricture --Prior/Concurrent Therapy-- No concurrent immunosuppressives --Patient Characteristics-- Hematopoietic: Absolute neutrophil count at least 2500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL Other: No active infection No fistula abscess No active inflammatory bowel disease Quiescent disease allowed, including: Chronic ulcerative colitis Crohn's disease No other significant immunologic disorder No active malignancy No active alcohol or drug abuse No pregnant or nursing women Effective contraception required of fertile patients Endoscopic retrograde cholangiopancreatography within 36 months prior to registration Liver biopsy within 12 months prior to registration

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: cladribine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gastrointestinal disorders, primary sclerosing cholangitis, rare disease
Cognitive Effects of Immunomodulatory Drugs in MS

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine and compare changes in the specific thinking skills of patients with RRMS who are receiving treatment with one of three immunomodulatory medications (Avonex, Copaxone, or Rebif).

Detailed Description
-----------------
In addition this study will compare the patients' personal view of how they are doing, any changes in physical disability, and the frequency and severity of relapses over the three year period.

Official Title
-----------------
Comparison of the Cognitive Effects of Three Immunomodulatory Drugs in Relapsing-Remitting Multiple Sclerosis: A Longitudinal Study

Conditions
-----------------
Multiple Sclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of RRMS for at least one year, Currently on one of three immunomodulatory drugs (Avonex, Copaxone, or Rebif), Visual Acuity is 20/50 or better, patient has four color vision, Must have at least a high school education Exclusion Criteria: History of head injury, drug/alcohol abuse, and/or psychiatric problems, -current diagnosis of a severe or lifethreatening disease other than MS, currently taking immunosuppressant medication, resides greater than 200 miles from the study site

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Subjects receiving Avonex | |
| 2<br>Subjects receiving Rebif | |
| 3<br>Subjects receiving Copaxone | |
| 4<br>Healthy controls | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Treatment of Late Abortion: Evacuatio Uteri or Conservative Treatment

Study Overview
=================
Brief Summary
-----------------
A randomize trial: expectation or evacuatio uteri for the treatment after late abortion

Detailed Description
-----------------
A randomize trial adressing 200 women consecutively recruited from clinical practice at Rigshospitalet.Expectation: administration of 800 microgram Cytotec half an hour after delivery. Surgery: Evacuation of the uterus

Official Title
-----------------
Evacuatio Uteri or Conservtive Treatment After Late Abortion. A Randomize Trial.

Conditions
-----------------
Abortion, Spontaneous, Abortion, Induced

Intervention / Treatment
-----------------
* Drug: Cytotec


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: abortion at gestational age (ultrasound) 14+0 - 20+0 Exclusion Criteria: Allergy to cytotec

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Cytotec|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Side-effect |  |  | 
| Complication |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Late abortion
The Development of an In-vitro System to Identify Gynecologic Cancer Cells During Surgical Procedures

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the efficacy of mid-infrared spectroscopy together with Attenuated Total Reflection (ATR), for the detection of gynecological malignancies in real time during surgery.

Conditions
-----------------
Gynecological Malignancies

Intervention / Treatment
-----------------
* Device: Mid-Infrared Spectroscopy with ATR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with one or more tumors in reproductive system Exclusion Criteria: Pregnant women Unable to give consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Frozen section<br>Frozen sections taken from women operated on for possible gynecologic malignancies. | Device: Mid-Infrared Spectroscopy with ATR<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gynecological Malignancies Identified in Real Time | Results of Spectroscopy will be compared to frozen section/histopathology findings | One hour |
A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if Dimebon is safe and effective in patients with moderate to severe Alzheimer's disease.

Official Title
-----------------
CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease

Conditions
-----------------
Moderate to Severe Alzheimer

Intervention / Treatment
-----------------
* Drug: Dimebon (latrepirdine)
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Moderate-to-Severe Alzheimer's disease Mini-Mental State Examination (MMSE) Score between 5 to 14, inclusive Stable on donepezil for at least 6 months Exclusion Criteria: Other causes of dementia Major structural brain disease Unstable medical condition or significant hepatic or renal disease

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dimebon (latrepirdine)<br>Dimebon, 20 mg orally three times daily | Drug: Dimebon (latrepirdine)<br>* 20 mg orally three times daily<br>|
| Placebo Comparator: Placebo<br>Placebo orally three times daily | Drug: Placebo<br>* Placebo orally three times daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neuropsychiatric Inventory (NPI) | To evaluate the efficacy of dimebon (latrepirdine) as compared to placebo on a measure of behavior, the Neuropsychiatric Inventory (NPI) | 26 weeks post baseline | 
| Activities of Daily Living (severe) (ADCS ADLsev) | To evaluate the efficacy of dimebon as compared to placebo on a measure of self-care and daily function, the Alzheimer's Disease Cooperative Study - Activities of Daily Living (severe) (ADCS ADLsev). | 26 weeks post baseline |
Organ Donation and Hydrocortisone Treatment

Study Overview
=================
Brief Summary
-----------------
Brain death patients who are selected for organ donation very often suffer from haemodynamic instability. To treat this, high amounts of vasoactive drugs(norepinephrine) may be needed to raise blood pressure. However,norepinephrine may have negative influence on several organs causing reduced blood flow ischemia. Our hypothesis is that hydrocortisone treatment may reduce the amount of vasoactive drugs needed to keep the blood pressure stable in patients selected for organ donation.

Detailed Description
-----------------
When patients are treated in the ICU only as possible organ donators they will be assessed for eligibility for the study. Iv hydrocortisone or placebo will be administered every 6 hours. Several hormonal samples will be collected.

Official Title
-----------------
Organ Donation and Vasopressor Use: Effects of Hydrocortisone Treatment

Conditions
-----------------
Brain Death

Intervention / Treatment
-----------------
* Drug: hydrocortisone
* Drug: sodium chloride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all have to be fulfilled severe brain injury or subarachnoid hemorrhage which progrediates to brain death and patients are treated only as candidates for organ donation in the ICU no other reasons for treatment than organ donation informed consent from official representative Exclusion Criteria: age under 18 pregnancy corticoid treatment before study entry adrenal insufficiency hypophyseal insufficiency treatment with etomidate one week before study entry participating in an other study no informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>hydrocortisone treatment 50mg iv x4 | Drug: hydrocortisone<br>* hydrocortisone 50mg iv. every 6 hours<br>|
| Placebo Comparator: 2<br>Placebo iv every 6 hours | Drug: sodium chloride<br>* sodium chloride every 6 hours iv<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| dosage and time on norepinephrine treatment |  | in ICU | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hormone levels and number of organs donated |  | Hospital treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
brain death, subarachnoid hemorrhage, traumatic brain injury, brain injury, intracerebral hemorrhage, organ donation